Key result
Enalapril significantly reduced systemic mean arterial blood pressure, glomerular capillary pressure, and renal lesions compared with placebo in dogs with induced chronic renal insufficiency.
Why the study?
Does enalapril reduce systemic arterial and glomerular capillary pressure and renal injury in dogs with induced chronic renal insufficiency?
Population
18 adult dogs with induced chronic renal insufficiency (renal mass reduced by partial nephrectomy)
Comparison
Enalapril 0.5 mg/kg, PO, q 12 h for 6 months vs Placebo for 6 months
Design
Preclinical
Follow-up
6 months
Authors
Loading...
Supports enalapril testing in canine CKD models; leaves open translation to spontaneous disease and clinical practice.
RCT (n=18)
Does enalapril reduce systemic arterial and glomerular capillary pressure and renal injury in dogs with induced chronic renal insufficiency?
Enalapril effectively modulates progressive renal injury and reduces systemic and glomerular hypertension in a canine model of chronic renal insufficiency.
Brown et al. (2003) conducted an RCT in induced chronic renal insufficiency (n=18). Enalapril vs. Placebo was evaluated on Systemic mean arterial blood pressure, glomerular capillary pressure, and renal injury. Enalapril significantly reduced systemic mean arterial blood pressure, glomerular capillary pressure, and renal lesions compared with placebo in dogs with induced chronic renal insufficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: